Stockscreener 앱 받기
182.34
1.33%
-2.45
시간 외 거래:
182.34
전일 마감가:
$184.79
열려 있는:
$188.81
하루 거래량:
1.03M
Relative Volume:
1.18
시가총액:
$8.78B
수익:
$4.03B
순이익/손실:
$-182.84M
주가수익비율:
-48.49
EPS:
-3.7603
순현금흐름:
$391.29M
1주 성능:
-2.12%
1개월 성능:
+20.88%
6개월 성능:
-6.96%
1년 성능:
+25.71%
1일 변동 폭
$181.72
$191.34
1주일 범위
$181.72
$191.34
52주 변동 폭
$143.06
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
182.34 | 9.08B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
LH vs. CRL: Which Stock Is the Better Value Option? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories Stock (US1591881009): shares in focus after recent earnings and valuation - AD HOC NEWS
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears - Insider Monkey
Top Charles River Laboratories International (CRL) Competitors 2026 - MarketBeat
Convert Charles River Laboratories International, Inc. (CRL) to New Taiwan dollar (TWD) - Crypto.com
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Recovery And Conflicting Fair Value Signals - simplywall.st
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Incyte (INCY) and Pfizer (PFE) - The Globe and Mail
Charles River (NYSE: CRL) director James C. Foster reports 366,722-share gift and trust transfers - Stock Titan
CRL (CRL) CEO shifts 6,772 shares via bona fide gifts, keeps large stake - Stock Titan
Charles River (NYSE: CRL) exec reports 3,058-share stock gifts and positions - Stock Titan
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL) - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
CRL Q1 2026 Earnings: EPS Surpasses Estimates, Stock Retreats Despite Profit BeatEstimate Uncertainty - newsline.com
Charles River Laboratories (CRL) Slips 2.4% as Key Support Levels LoomSwing Entry Signals - newsline.com
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Can Charles River’s Portfolio Divestitures and “Pathway to Purpose” Strategy Reframe the CRL Investment Narrative? - simplywall.st
Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says - marketscreener.com
Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation Signals - Yahoo Finance
Charles River (CRL) director awarded 422 restricted stock units as fees - Stock Titan
CRL: New strategy targets margin gains, tech integration, and growth, with DSA momentum building - TradingView
Charles River Laboratories International Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow (NYSE:CRL) 2026-06-03 - Seeking Alpha
Charles River Laboratories International Inc (CRL) Shares Fall 4 - GuruFocus
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71 - Stock Titan
CRL (NYSE: CRL) CIO receives stock grant; shares withheld for taxes - Stock Titan
Charles River (NYSE: CRL) EVP awarded 5,257 shares, 979 withheld - Stock Titan
CRL (NYSE: CRL) SVP Michael Knell awarded 1,837 shares, 200 used for tax withholding - Stock Titan
Charles River (NYSE: CRL) CEO awarded shares, withholds stock to pay tax - Stock Titan
James C. Foster (CRL) records tax-withholding share disposition and updates indirect holdings - Stock Titan
Charles River (NYSE: CRL) EVP gets 5,135-share award with tax withholding - Stock Titan
Charles River (NYSE: CRL) executive reports stock grant and tax withholding - Stock Titan
CRL: Operational efficiency, innovation, and portfolio focus drive growth and resilience - TradingView
CRL: Modernization, AI, and NAMs drive growth and margin expansion, with renewed DSA momentum - TradingView
Charles River Laboratories International Inc at William Blair Growth Stock Conference Transcript - GuruFocus
Charles River Shareholder Notice - TMX Newsfile
Charles River Laboratories to Present at William Blair and Jefferies Conferences 2026 - BioSpace
Charles River Laboratories (CRL) to Present at Key Investor Conf - GuruFocus
Charles River Laboratories to Present at William Blair and Jefferies Conferences - pharmiweb.com
CLSA upgrades Charles River Laboratories International (CRL) - MSN
Charles River Laboratories (CRL) Slides Slightly, Holds Near Key ResistanceMarket Cap Weight - thelegaladvocate.com
Charles River Laboratories Hits Day High with 10.24% Surge in Stock Price - Markets Mojo
CLSA upgrades Charles River Labs stock rating on regulatory outlook - Investing.com UK
CLSA upgrades Charles River Labs stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.63%
2.88%
자본화:
|
볼륨(24시간):